Scott Shofer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Scott Shofer has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Neelima Navuluri
Duke University School of Medicine Division of Pulmonary, Allergy, and Critical Care, Department of Medicine Durham, North Carolina
2 shared publications - Abigail Shapiro
Durham VA Health Care System
1 shared publication - Amritpal Singh
Emory University Computer Science and Informatics Atlanta, GA, USA
1 shared publication Amy L. Lark
Department of Pathology, Duke University Medical Center, Durham, NC, U.S.A.
1 shared publication- Anant Madabhushi
Department of Biomedical Engineering, Emory University, Atlanta, GA
1 shared publication Angela B. Johnson
1 shared publication
Latest Publications
- Open Access
- 9 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Peri-aortic fat to assess cardiovascular aging using an AI-driven radiomic biomarker
Background and Aims: Chronological age is central to cardiovascular disease (CVD) risk estimation but poorly reflects interindividual heterogeneity in cardiovascular aging. This study developed a peri-aortic adipose tissue (PAAT) radiomic cardiovascular age (CV-Age) biomarker from routine chest CT and tested whether the PAAT age gap (ΔAge = CV-Age − chronological age) stratifies major adverse cardiovascular events (MACE) and improves risk classification. Methods: Four chest CT cohorts with different protocols were utilized to train (n = 4451) and externally validate (n = 44 214) a CV-Age model. Associations between ΔAge decile groups (resilient ≤10th; accelerated ≥90th) and incident 5-point MACE (myocardial infarction, stroke, revascularization, heart failure, and death) were assessed using survival models. Clinical utility was evaluated by substituting CV-Age for chronological age in PREVENT to quantify risk reclassification. Results: A 31-feature radiomic signature capturing PAAT volume, attenuation, and texture heterogeneity predicted age with good accuracy (training MAE 2.2 years; primary external validation MAE 2.7 years). In a separate higher-risk cohort, predictions showed a positive ΔAge (median +5.4 years), reflecting elevated baseline cardiovascular burden. ΔAge-stratified event-free survival differed across groups (log-rank P < .001); compared with normative agers, accelerated agers had higher MACE risk (HR 1.51, 95% CI 1.37–1.66), and resilient agers had lower risk (HR 0.70, 0.63–0.77). Substituting CV-Age into PREVENT improved risk reclassification (categorical NRI +0.03, P < .01, continuous NRI +0.04, P < .05). Conclusions: Radiomic profiling of PAAT on routine chest CT yields a scalable imaging biomarker of cardiovascular aging. CV-Age can help improve identification of higher-risk individuals missed by age-driven risk estimation, supporting its role as a risk-enrichment tool.
- 9 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Open AccessPeri-aortic fat to assess cardiovascular aging using an AI-driven radiomic biomarker
Background and Aims: Chronological age is central to cardiovascular disease (CVD) risk estimation but poorly reflects interindividual heterogeneity in cardiovascular aging. This study developed a peri-aortic adipose tissue (PAAT) radiomic cardiovascular age (CV-Age) biomarker from routine chest CT and tested whether the PAAT age gap (ΔAge = CV-Age − chronological age) stratifies major adverse cardiovascular events (MACE) and improves risk classification. Methods: Four chest CT cohorts with different protocols were utilized to train (n = 4451) and externally validate (n = 44 214) a CV-Age model. Associations between ΔAge decile groups (resilient ≤10th; accelerated ≥90th) and incident 5-point MACE (myocardial infarction, stroke, revascularization, heart failure, and death) were assessed using survival models. Clinical utility was evaluated by substituting CV-Age for chronological age in PREVENT to quantify risk reclassification. Results: A 31-feature radiomic signature capturing PAAT volume, attenuation, and texture heterogeneity predicted age with good accuracy (training MAE 2.2 years; primary external validation MAE 2.7 years). In a separate higher-risk cohort, predictions showed a positive ΔAge (median +5.4 years), reflecting elevated baseline cardiovascular burden. ΔAge-stratified event-free survival differed across groups (log-rank P < .001); compared with normative agers, accelerated agers had higher MACE risk (HR 1.51, 95% CI 1.37–1.66), and resilient agers had lower risk (HR 0.70, 0.63–0.77). Substituting CV-Age into PREVENT improved risk reclassification (categorical NRI +0.03, P < .01, continuous NRI +0.04, P < .05). Conclusions: Radiomic profiling of PAAT on routine chest CT yields a scalable imaging biomarker of cardiovascular aging. CV-Age can help improve identification of higher-risk individuals missed by age-driven risk estimation, supporting its role as a risk-enrichment tool.
- Open Access
- 18 March 2025
- Published by Elsevier in CHEST Pulmonary
- Vol. 3 (3)
“They Just Don’t Get Around to It”
- 18 March 2025
- Published by Elsevier in CHEST Pulmonary
- Vol. 3 (3)
Open Access“They Just Don’t Get Around to It”
- Open Access
- 1 January 2013
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 14, 253-257
Endobronchial metastasis from primary anorectal melanoma
Background: Anorectal melanoma is a rare cancer with a poor prognosis. The mean survival after diagnosis is 15–25 months. At the time of diagnosis, 61% of patients have local regional lymph node metastases, and 21% have distant metastases. The lung...
- 1 January 2013
- Published by International Scientific Information, Inc. in American Journal of Case Reports
- Vol. 14, 253-257
Open AccessEndobronchial metastasis from primary anorectal melanoma
Background: Anorectal melanoma is a rare cancer with a poor prognosis. The mean survival after diagnosis is 15–25 months. At the time of diagnosis, 61% of patients have local regional lymph node metastases, and 21% have distant metastases. The lung...
- Open Access
- 1 November 2008
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 3 (11) , 1361-1362
Formation of a Bronchoesophageal Fistula Following Concurrent Radiation and Chemotherapy for Lung Cancer in the Setting of Behçet's Disease
- 1 November 2008
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 3 (11) , 1361-1362
Open AccessFormation of a Bronchoesophageal Fistula Following Concurrent Radiation and Chemotherapy for Lung Cancer in the Setting of Behçet's Disease